

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 July 2023 (06.07.2023)



(10) International Publication Number
WO 2023/130008 A8

(51) International Patent Classification:

C07D 217/16 (2006.01) C07D 257/04 (2006.01)
A61K 31/41 (2006.01) C07D 403/06 (2006.01)
A61K 31/4725 (2006.01) A61P 25/08 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/082532

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

29 December 2022 (29.12.2022)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(88) Date of publication of the international search report:

10 August 2023 (10.08.2023)

(30) Priority Data:

63/266,327 01 January 2022 (01.01.2022) US

(48) Date of publication of this corrected version:

14 September 2023 (14.09.2023)

(71) Applicant: SEA PHARMACEUTICALS LLC [US/US];
14 Gray Street, Cambridge, Massachusetts 02138 (US).

(15) Information about Correction:

see Notice of 14 September 2023 (14.09.2023)

(72) Inventors: PEARSON, James Philip; 14 Gray Street, Cambridge, Massachusetts 02138 (US). MARTINEZ, Eduardo J.; 632 Dayton Rd., Bryn Mawr, Pennsylvania 19010 (US). SENANAYAKE, Chris H.; 12 Isabels Way Road, Brookfield, Connecticut 06804 (US). HONG, Yaping; 4 Maidenhead Road, Princeton, New Jersey 08540 (US). CHAKRABORTY, Arindam; 1914 Hunters Glen Drive, Plainsboro, New Jersey 08536 (US).

(74) Agent: BRULE, Christina E.; 5 Columbia Circle, Albany, New York 12203 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF

(57) Abstract: 6-(2-(2H-tetrazol-5-yl)ethyl)decahydroisoquinoline-3-carboxylic acid and derivatives thereof, of formulas are disclosed, as are pharmaceutical compositions and methods for the treatment of epilepsy and seizure disorders employing those compositions, including heritable genetic seizure disorders, seizure-disorder that result from a brain tumor, traumatic brain injury, or head injury, or seizure-disorder that result from brain injury during or after viral infection, bacterial infection, parasitic infection, prion disease or idiopathic causes.

